Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Public ClinicalTrials.gov record NCT03112174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Study identification
- NCT ID
- NCT03112174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 366 participants
Conditions and interventions
Conditions
Interventions
- Ibrutinib Drug
- Placebo Oral tablet to match Venetoclax Drug
- Venetoclax Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 18, 2017
- Primary completion
- Jun 25, 2024
- Completion
- Jun 26, 2024
- Last update posted
- Jul 21, 2025
2017 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Centre-North Campus | Tucson | Arizona | 85719 | — |
| City of Hope | Duarte | California | 91010 | — |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles | California | 90095 | — |
| Orlando Health Inc. | Orlando | Florida | 32806 | — |
| The University of Kansas Cancer Center and Medical Pavilion | Westwood | Kansas | 66205 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Barbara Ann Karmanos Cancer institute | Detroit | Michigan | 48201 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Stony Brook University | New York | New York | 11794 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| University of Tennessee medical Center | Knoxville | Tennessee | 37920 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98194 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 106 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03112174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2025 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03112174 live on ClinicalTrials.gov.